NCCN Guidelines & Expanded Recommendations for Germline Testing Based on Tumor Genomic Testing Results

10.04.2020 - By Genotypecast with Grey Genetics

Download our free app to listen on your phone

Karen Huelsman MS, LGC discusses recent NCCN guideline updates which expand  genetic testing criteria (for high-penetrance hereditary breast and/or ovarian cancer susceptibility genes) to include any mutation identified on tumor  testing that has clinical implications if also identified in the germline. She discusses these updated recommendations in the context of the evolution of tumor genomic testing, commercially available paired tumor testing, and her role as a Precision Medicine Oncology Genetic Counselor.
Find Karen on Twitter: @Karen_GC_Cincin and on LinkedIn

Related Links and Resources
NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer (free to access but requires login)
Fassi, Emily. “NCCN Guidelines: Recent updates to the Genetic/Familial High-Risk Assessment for Breast, Ovarian, and Pancreatic Cancers (version 1.2021).” September 28, 2020. Grey Genetics News Corner.
TriHealth Genetic Counseling in Cincinnati, OH

Do you have questions or topics you’d like a genetic counselor to discuss on a future episode ?
Leave us a short voice message here! We may use your message on a future show.

Are you looking for genetic counseling?
Grey Genetics is an independent telehealth genetic counseling and consulting company. Book an appointment with a genetic counselor specialized in your area of concern. All genetic counseling appointments take place over secure, HIPAA-compliant video-conferencing or by phone.
Grey Genetics on Twitter: @GreyGenetics
Grey Genetics on Instagram: @greygenetics
Grey Genetics on Facebook
Grey Genetics on LinkedIn

More episodes from Genotypecast with Grey Genetics